Study of Efficacy of Oral Sacubitril/Valsartan in Adult Patients With Non-obstructive Hypertrophic Cardiomyopathy
Status:
Recruiting
Trial end date:
2023-05-04
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if LCZ696 is safe, tolerable and can improve
exercise capacity (via improved peak VO2) in non-obstructive HCM patient population over the
course of 50 weeks of treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Novartis Pharmaceuticals
Treatments:
LCZ 696 Sacubitril and valsartan sodium hydrate drug combination Valsartan